Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Gynecologic 2Breast 2

Conditions

Breast Neoplasms 58Ovarian Neoplasms 7Neoplasm Metastasis 7Endometrial Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Neoplasms 4Hereditary Sensory and Autonomic Neuropathies 4Advanced Breast Cancer 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Colorectal Neoplasms 3Neoplasms by Site 2Head and Neck Neoplasms 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2Advanced Solid Tumors 2Advanced Solid Tumor 2Unilateral Breast Neoplasms 1Spinocerebellar Degenerations 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Melanoma 1Lung Neoplasms 1Locoregional Recurrence 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1HR+/HER2- Breast Cancer 1HR+ Breast Cancer 1

Interventions

Cisplatin 4atezolizumab 3Nivolumab 3Carboplatin 3pembrolizumab 2entrectinib 2cobimetinib 2capmatinib 2alectinib 2abemaciclib 2Vemurafenib 2Radiosurgery 2Pemetrexed 2Mitomycin 2Fulvestrant 2Drug Therapy 2Bevacizumab 2130-nm albumin-bound paclitaxel 2spartalizumab 1ribociclib 1repotrectinib 1relatlimab 1relacorilant 1pertuzumab 1palbociclib 1olaparib 1lutetium Lu 177 dotatate 1exemestane 1enzalutamide 1enfortumab vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Neoplasms by Site × Fulvestrant × Clear all
NCT05768139 2026-06-04

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06993844 2026-05-06

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Ensem Therapeutics

Phase 1/2 Recruiting
233 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡